MENU
+Compare
YMAB
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$4.80
Change
+$0.30 (+6.67%)
Capitalization
217.05M

YMAB Y-mAbs Therapeutics Forecast, Technical & Fundamental Analysis

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company... Show more

YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for YMAB with price predictions
Apr 02, 2025

YMAB in +8.35% Uptrend, advancing for three consecutive days on April 02, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where YMAB advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where YMAB's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for YMAB just turned positive on March 19, 2025. Looking at past instances where YMAB's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

YMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on YMAB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for YMAB entered a downward trend on March 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.359) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.427) is also within normal values, averaging (252.036).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. YMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

YMAB is expected to report earnings to rise 27.40% to -19 cents per share on May 12

Y-mAbs Therapeutics YMAB Stock Earnings Reports
Q1'25
Est.
$-0.19
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.09
Q1'24
Missed
by $0.01
The last earnings report on March 04 showed earnings per share of -15 cents, missing the estimate of -11 cents. With 238.83K shares outstanding, the current market capitalization sits at 217.05M.
A.I. Advisor
published General Information

General Information

a developer of novel antibody therapeutics for oncology targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFETX49.190.16
+0.33%
Janus Henderson European Focus T
BIGIX27.46N/A
N/A
William Blair International Growth I
OIGAX32.00N/A
N/A
Invesco Oppenheimer International Gr A
LGCAX16.43N/A
N/A
Lord Abbett Global Equity A
FSYNX9.06N/A
N/A
Fidelity Advisor Sustainable EM Eq M

YMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with FATE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+6.67%
FATE - YMAB
46%
Loosely correlated
+1.70%
CRSP - YMAB
44%
Loosely correlated
+3.17%
ARWR - YMAB
44%
Loosely correlated
+3.97%
IPSC - YMAB
43%
Loosely correlated
+3.96%
RCKT - YMAB
42%
Loosely correlated
+8.43%
More